Study S000582

Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in East Asian Participants With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05132088
Acronym: OASIS 2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 201
Start: 2021-11-16
Primary completion: 2023-07-11
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight and Obesity
Interventions: DRUG:semaglutide 50 mg; DRUG:placebo (semaglutide)
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1258-7561

Registered primary outcomes

Percent Change From Baseline in Body Weight [Baseline (week 0), week 68]
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No) [At week 68]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0034356	Perspectives and Insights on Glucagon-Like Peptide-1 Receptor Agonists: From Development to Submission of a Clinical Trial Application in Canada Mihirkumar Patel, Zenodo (CERN European Organization for Nuclear Research)	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT05132088
R0006183	Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. Kadowaki T, JAMA internal medicine	2025	Randomized trial	PMID 40758358 DOI	cites ClinicalTrials.gov:NCT05132088; registry reference DERIVED:40758358